• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pharvaris N.V. (NQ: PHVS )

    20.35 -0.20 (-0.97%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pharvaris N.V.

    < Previous 1 2 3 4 5 Next >
    Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
    Via Benzinga
    8 Analysts Have This to Say About Pharvaris
    Via Benzinga
    Analyst Expectations for Pharvaris's Future
    Via Benzinga
    Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks traded lower, with the Dow Jones falling around 300 points on Tuesday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
    From Pharvaris N.V.
    Via GlobeNewswire
    Why Shares of Pharvaris N.V. Are Up Tuesday
    Promising news from the Food and Drug Administration spurred the healthcare stock's rise. 
    Via The Motley Fool
    5 Analysts Have This to Say About Pharvaris
    Via Benzinga
    What 4 Analyst Ratings Have To Say About Pharvaris
    Via Benzinga
    FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE
    Pharvaris NV (NASDAQ: PHVS) announced that the FDA lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant (PHA-121) for the on-demand  
    Via Benzinga
    Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Announces $70 Million Private Placement Financing
    From Pharvaris N.V.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! 
    Via InvestorPlace
    Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Announces Annual Meeting of Shareholders
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Present in Upcoming March Investor Conferences
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
    From Pharvaris N.V.
    Via GlobeNewswire
    Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday. 
    Via Benzinga
    Pharvaris to Present at SVB Securities Global Biopharma Conference
    From Pharvaris N.V.
    Via GlobeNewswire
    Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
    U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday
    U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Wednesday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    Pharvaris Provides Regulatory, Clinical, and Corporate Updates
    From Pharvaris N.V.
    Via GlobeNewswire
    EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
    Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
    Via Benzinga
    Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
    Via Benzinga
    Dow Tumbles 150 Points; Crude Oil Falls Sharply
    U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday. 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.